Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

261. Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism

Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism Evidence-based Synthesis Program Department of Veterans Affairs Health Services Research & Development Service April 2012 Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-term Prevention and Treatment of Arterial and Venous Thromboembolism Prepared for: Department of Veterans Affairs Veterans Health Administration (...) . Warfarin and Newer Oral Anticoagulants: Long-term Prevention and Treatment of Arterial and VTE Evidence-based Synthesis Program PREFACE Quality Enhancement Research Initiative’s (QUERI’s) Evidence-based Synthesis Program (ESP) was established to provide timely and accurate syntheses of targeted healthcare topics of particular importance to Veterans Affairs (V A) managers and policymakers, as they work to improve the health and healthcare of Veterans. The ESP disseminates these reports throughout V

2012 Veterans Affairs Evidence-based Synthesis Program Reports

262. Should Patients With Nephrotic Syndrome Receive Anticoagulation?

Should Patients With Nephrotic Syndrome Receive Anticoagulation? Should Patients With Nephrotic Syndrome Receive Anticoagulation? – Clinical Correlations Search Should Patients With Nephrotic Syndrome Receive Anticoagulation? May 9, 2012 5 min read By Jennifer Mulliken Faculty Peer Reviewed Case 1: A 30-year-old African-American male with a history of bilateral pulmonary emboli presents with a 1-week history of bilateral lower extremity edema. Blood pressure is 138/83, cholesterol 385, LDL 250 (...) , albumin 2.9. Urinalysis shows 3+ protein. Twenty-four hour urinary protein is 7.2 grams. Case 2: A 47-year-old Hispanic male with a history of mild hypertension and venous insufficiency presents with a 3-month history of bilateral lower extremity edema. BP is 146/95, cholesterol 241, LDL 165, albumin 1.9. Urinalysis shows 3+ protein. Twenty-four hour urinary protein is 4.6 grams. What is the evidence to support prophylactic anticoagulation in patients with nephrotic syndrome? Nephrotic syndrome

2012 Clinical Correlations

263. Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies

Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-analysis of controlled studies Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

264. The business case for quality improvement: oral anticoagulation for atrial fibrillation Full Text available with Trip Pro

The business case for quality improvement: oral anticoagulation for atrial fibrillation The business case for quality improvement: oral anticoagulation for atrial fibrillation The business case for quality improvement: oral anticoagulation for atrial fibrillation Rose AJ, Berlowitz DR, Ash AS, Ozonoff A, Hylek EM, Goldhaber-Fiebert JD Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to evaluate the cost-effectiveness of a quality improvement programme to improve blood coagulation control for patients with atrial fibrillation who were on anticoagulants to prevent stroke. The programme was likely to be cost-saving for the payer, even if it was only modestly effective and more expensive than similar programmes. Given

2012 NHS Economic Evaluation Database.

265. New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation

New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation | CADTH.ca Find the information you need New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation New Oral Anticoagulants for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation Published on: January 31, 2012 Project (...) Number: TR0002 Product Line: Therapeutic Review Result type: Report Warfarin has been the mainstay of oral anticoagulant therapy for many years. Now, new oral anticoagulants are being used to prevent stroke and other thromboembolic events in patients with atrial fibrillation. This project assessed the newer oral anticoagulants: dabigatran (Pradax), rivaroxaban (Xarelto), and apixaban (Eliquis). Related projects : An extension to this project, which will include antiplatelet drugs

2012 CADTH - Therapeutic Review

266. New anticoagulants: a well-dosed introduction

New anticoagulants: a well-dosed introduction New anticoagulants: a well-dosed introduction New anticoagulants: a well-dosed introduction Health Council of the Netherlands Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Council of the Netherlands. New anticoagulants: a well-dosed introduction. The Hague: Health Council of the Netherlands Gezondheidsraad (...) (GR). 2012/07E. 2012 Authors' objectives Currently nearly 400,000 people in the Netherlands are being treated with anticoagulants of a type Vitamin K antagonists (VKAs). Although VKAs are very effective in treating and preventing thrombosis and embolisms, there are some important disadvantages to taking these 'blood thinners' on a daily basis. The primary objection is that treatment with VKAs requires intensive supervision and monitoring. VKAs also interact with a large number of foods and other

2012 Health Technology Assessment (HTA) Database.

267. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

268. A meta-analysis to determine the effect of anticoagulation on mortality in patients with blunt head trauma

A meta-analysis to determine the effect of anticoagulation on mortality in patients with blunt head trauma Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

269. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation

Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

270. Self monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data

Self monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

271. Antiplatelet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis

Antiplatelet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

272. Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation

Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

273. Should My Patient with a Solid Tumor be Anticoagulated in the Absence of Venous Thromboembolism?

Should My Patient with a Solid Tumor be Anticoagulated in the Absence of Venous Thromboembolism? Should My Patient with a Solid Tumor be Anticoagulated in the Absence of Venous Thromboembolism? – Clinical Correlations Search Should My Patient with a Solid Tumor be Anticoagulated in the Absence of Venous Thromboembolism? September 8, 2011 6 min read By David Altszuler, Class of 2012 Faculty Peer Reviewed An empiric association between occult malignancy and thrombophlebitis has been recognized (...) since Trousseau first reported the syndrome in 1865.[1] The mechanism by which cancer predisposes to thrombophilia has not been fully elucidated; however, it is now clear that this is a symbiotic relationship.[2] The second leading cause of death in hospitalized cancer patients (and a leading .[3] There are algorithms to identify cancer patients at high risk for developing venous thromboembolism (VTE), and a recently undertaken clinical trial exploring the efficacy of anticoagulation prophylaxis

2011 Clinical Correlations

274. A New Era for Anticoagulation in Atrial Fibrillation. Full Text available with Trip Pro

A New Era for Anticoagulation in Atrial Fibrillation. 21870977 2011 09 27 2015 11 19 1533-4406 365 11 2011 Sep 15 The New England journal of medicine N. Engl. J. Med. A new era for anticoagulation in atrial fibrillation. 1052-4 10.1056/NEJMe1109748 Mega Jessica L JL eng Comment Editorial 2011 08 27 United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Benzimidazoles 0 Morpholines 0 Pyrazoles 0 Pyridones 0 Thiophenes 11P2JDE17B beta-Alanine 3Z9Y7UWC1J apixaban 5Q7ZVV76EI Warfarin (...) 9NDF7JZ4M3 Rivaroxaban I0VM4M70GC Dabigatran AIM IM N Engl J Med. 2012 Jan 5;366(1):88-9; author reply 89-90 22216850 N Engl J Med. 2011 Sep 15;365(11):981-92 21870978 N Engl J Med. 2011 Sep 8;365(10):883-91 21830957 N Engl J Med. 2009 Sep 17;361(12):1139-51 19717844 Anticoagulants therapeutic use Atrial Fibrillation drug therapy Benzimidazoles therapeutic use Dabigatran Humans Morpholines therapeutic use Pyrazoles therapeutic use Pyridones therapeutic use Rivaroxaban Stroke prevention & control

2011 NEJM

275. New Options in Anticoagulation for Atrial Fibrillation. Full Text available with Trip Pro

New Options in Anticoagulation for Atrial Fibrillation. 21830960 2011 09 16 2016 10 25 1533-4406 365 10 2011 Sep 08 The New England journal of medicine N. Engl. J. Med. New options in anticoagulation for atrial fibrillation. 952-3 10.1056/NEJMe1107516 del Zoppo Gregory J GJ Eliasziw Misha M eng R01 NS053716 NS NINDS NIH HHS United States R37 NS038710 NS NINDS NIH HHS United States Comment Editorial 2011 08 10 United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Benzimidazoles 0 (...) Morpholines 0 Thiophenes 11P2JDE17B beta-Alanine 5Q7ZVV76EI Warfarin 9NDF7JZ4M3 Rivaroxaban I0VM4M70GC Dabigatran AIM IM N Engl J Med. 2011 Sep 8;365(10):883-91 21830957 N Engl J Med. 2009 Sep 17;361(12):1139-51 19717844 Anticoagulants therapeutic use Atrial Fibrillation drug therapy Benzimidazoles therapeutic use Dabigatran Humans Intention to Treat Analysis Intracranial Hemorrhages chemically induced Morpholines therapeutic use Rivaroxaban Thiophenes therapeutic use Warfarin therapeutic use beta-Alanine

2011 NEJM

276. Low Dose Vitamin K Supplementation and Anticoagulation Control

Low Dose Vitamin K Supplementation and Anticoagulation Control Low Dose Vitamin K Supplementation and Anticoagulation Control – Clinical Correlations Search Low Dose Vitamin K Supplementation and Anticoagulation Control July 21, 2011 7 min read By Joanna Becker Faculty Peer Reviewed Patients who are placed on long-term warfarin ( Coumadin ) therapy are sent home with a lengthy list of restrictions to minimize variations in warfarin efficacy. The agents that can alter warfarin levels can (...) be divided into 2 categories: (1) those that interact with cytochrome P450, which metabolizes warfarin and (2) those that alter phytonadione (vitamin K) levels. The majority of inter- and intra-individual warfarin dose variability is attributable to the agents in category 1 above, which include everything from antibiotics, antihistamines, and barbiturates to alcohol and antacids. However, once one controls for these variables, oral intake of vitamin K persists as an integral factor in anticoagulation

2011 Clinical Correlations

277. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. Full Text available with Trip Pro

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial.The RE-LY trial randomized 18

2011 EvidenceUpdates Controlled trial quality: uncertain

278. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes

Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

279. Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran. Full Text available with Trip Pro

Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran. 21488759 2011 06 01 2015 11 19 1533-4406 364 19 2011 May 12 The New England journal of medicine N. Engl. J. Med. Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran. 1788-90 10.1056/NEJMp1103050 Beasley B Nhi BN Division of Cardiovascular and Renal Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA (...) . Unger Ellis F EF Temple Robert R eng Journal Article 2011 04 13 United States N Engl J Med 0255562 0028-4793 0 Anticoagulants 0 Benzimidazoles 11P2JDE17B beta-Alanine 5Q7ZVV76EI Warfarin I0VM4M70GC Dabigatran AIM IM Anticoagulants administration & dosage adverse effects Atrial Fibrillation drug therapy Benzimidazoles administration & dosage adverse effects Dabigatran Drug Approval Embolism prevention & control Hemorrhage chemically induced Humans Stroke prevention & control Therapeutic Equivalency

2011 NEJM

280. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort Full Text available with Trip Pro

Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort The risk of stroke in patients with atrial fibrillation (AF) is not homogeneous, and various clinical risk factors have informed the development of stroke risk stratification schemes (RSS). Among anticoagulated cohorts, the emphasis should be on the identification of patients who remain at high risk for stroke (...) despite anticoagulation.We investigated predictors of thromboembolism (TE) risk in an anticoagulated AF clinical trial cohort (n = 7329 subjects) and tested the predictive value of contemporary RSS in this cohort: CHADS₂, Framingham, NICE 2006, American College of Cardiology/American Heart Association/European Society of Cardiology 2006, the 8th American College of Chest Physicians guidelines and the CHA₂DS₂-VASc schemes.On multivariate analysis, significant predictors of TE were stroke/TIA (hazard

2011 EvidenceUpdates